公开(公告)号：US20050170438A1

公开(公告)日：2005-08-04

申请号：US11041029

申请日：2005-01-21

申请人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

发明人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

IPC分类号： A61K31/275 ,  G01N33/53 ,  G01N33/542 ,  G01N33/567 ,  G01N33/574 ,  G01N33/68

CPC分类号： G01N33/542 ,  G01N33/57492 ,  G01N33/6803 ,  G01N33/6842 ,  G01N33/6872 ,  G01N2333/485 ,  G01N2333/49 ,  G01N2800/52

摘要： Abstract of the Disclosure The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

摘要翻译： 摘要揭示本发明涉及一种包含ErbB细胞表面膜受体二聚体的患者样品中的一类新生物标志物。 在一个方面，本发明包括通过将这样的病症与在患者样品，特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面，本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法，包括存在或 不存在癌前状态，存在或不存在癌症状态，癌症预后或对治疗的反应性。 优选地，本发明的方法通过使用具有可释放分子标签的结合化合物来实现，所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后，分离标签被释放并与测定混合物分离，用于分析。

公开(公告)号：USRE44437E1

公开(公告)日：2013-08-13

申请号：US13352705

申请日：2012-01-18

申请人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

发明人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

IPC分类号： G01N33/574

CPC分类号： G01N33/542 ,  G01N33/57492 ,  G01N33/6803 ,  G01N33/6842 ,  G01N33/6872 ,  G01N2333/485 ,  G01N2333/49 ,  G01N2800/52

摘要： The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

摘要翻译： 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面，本发明包括通过将这样的病症与在患者样品，特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面，本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法，包括存在或 不存在癌前状态，存在或不存在癌症状态，癌症预后或对治疗的反应性。 优选地，本发明的方法通过使用具有可释放分子标签的结合化合物来实现，所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后，分离标签被释放并与测定混合物分离，用于分析。

公开(公告)号：US20110275096A1

公开(公告)日：2011-11-10

申请号：US13103509

申请日：2011-05-09

申请人： Sean C. Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

发明人： Sean C. Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

IPC分类号： G01N33/566 ,  G01N33/53

CPC分类号： G01N33/5041 ,  G01N33/5064 ,  G01N33/5091 ,  G01N33/574 ,  G01N2333/515 ,  G01N2333/71 ,  G01N2800/52 ,  Y10S436/824

摘要： Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.

摘要翻译： 提供了方法，组合物和试剂盒，用于通过敏感，直接检测分子水平的内皮细胞活化来评估血管发生。 通常，通过测量参与内皮细胞中特异性血管生成信号传导途径的细胞成分及其蛋白质复合物的水平来检测内皮细胞的活化。 该方法可以用于评估与不期望的血管生成相关的疾病的状态，例如发展疾病的可能性，疾病的存在或不存在，疾病的预后以及对特定抗血管生成疗法的反应或抗性的可能性。 该方法还可用于指导针对特定血管生成信号通路的有效治疗方案的设计，以及与不期望的血管发生相关的疾病或病症的治疗干预。

公开(公告)号：US07939267B2

公开(公告)日：2011-05-10

申请号：US11267870

申请日：2005-11-03

申请人： Sean C. Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

发明人： Sean C. Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

IPC分类号： G01N33/53 ,  G01N33/566 ,  G01N33/58 ,  G01N33/567 ,  G01N33/535

CPC分类号： G01N33/5041 ,  G01N33/5064 ,  G01N33/5091 ,  G01N33/574 ,  G01N2333/515 ,  G01N2333/71 ,  G01N2800/52 ,  Y10S436/824

摘要： Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.

摘要翻译： 提供了方法，组合物和试剂盒，用于通过敏感，直接检测分子水平的内皮细胞活化来评估血管发生。 通常，通过测量参与内皮细胞中特异性血管生成信号传导途径的细胞成分及其蛋白质复合物的水平来检测内皮细胞的活化。 该方法可以用于评估与不期望的血管生成相关的疾病的状态，例如发展疾病的可能性，疾病的存在或不存在，疾病的预后以及对特定抗血管生成疗法的反应或抗性的可能性。 该方法还可用于指导针对特定血管生成信号通路的有效治疗方案的设计，以及与不期望的血管发生相关的疾病或病症的治疗干预。

公开(公告)号：US07771929B2

公开(公告)日：2010-08-10

申请号：US10420549

申请日：2003-04-18

申请人： Sharat Singh ,  Tracy Matray ,  Hossein Salimi-Moosavi

发明人： Sharat Singh ,  Tracy Matray ,  Hossein Salimi-Moosavi

IPC分类号： C07B61/00 ,  C07H21/00

CPC分类号： C40B70/00 ,  C07H21/00 ,  C40B50/16

摘要： Families of compositions are provided as labels, referred to as eTag reporters for attaching to polymeric compounds and assaying based on release of the eTag reporters from the polymeric compound and separation and detection. For oligonucleotides, the eTag reporters are synthesized at the end of the oligonucleotide by using phosphite or phosphate chemistry, whereby mass-modifying regions, charge-modifying regions and detectable regions are added sequentially to produce the eTag labeled reporters. By using small building blocks and varying their combination large numbers of different eTag reporters can be readily produced attached to a binding compound specific for the target compound of interest for identification. Protocols are used that release the eTag reporter when the target compound is present in the sample.

摘要翻译： 提供组合物家族作为标记，被称为eTag报告基因，用于附着于聚合物上，并基于从高分子化合物释放eTag报告物并进行分离和检测。 对于寡核苷酸，通过使用亚磷酸酯或磷酸酯化学在寡核苷酸的末端合成eTag报告物，由此顺序加入质量修饰区域，电荷修饰区域和可检测区域以产生eTag标记的记录。 通过使用小的构建块并改变它们的组合，可以容易地产生大量不同的eTag报告物，其连接到目的化合物特异性的结合化合物用于鉴定。 当目标化合物存在于样品中时，使用释放eTag报告物的方案。

公开(公告)号：US20090011432A1

公开(公告)日：2009-01-08

申请号：US12177049

申请日：2008-07-21

申请人： Po-Ying Chan-Hui ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Hasan Tahir ,  Gerald J. Wallweber ,  Hrair Kirakosssian ,  Tracy J. Matray

发明人： Po-Ying Chan-Hui ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Hasan Tahir ,  Gerald J. Wallweber ,  Hrair Kirakosssian ,  Tracy J. Matray

IPC分类号： G01N33/53 ,  G01N33/573

CPC分类号： G01N33/542 ,  G01N33/566 ,  G01N2333/71 ,  G01N2333/726 ,  Y10S436/824

摘要： Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.

摘要翻译： 提供了用于检测样品（例如细胞或组织裂解物）中分子复合物（特别是蛋白质）的形成的方法。 在一个方面，提供了对复合物中的第一种蛋白质特异性的切割探针和一种或多种特异于复合物中的一种或多种第二种蛋白质的结合化合物。 在结合时，诱导切割探针以产生仅在切割探针的局部区域中切割附着于结合化合物的分子标签的活性物质，例如单线态氧。 将释放的分子标签与测定混合物和彼此分离，以提供与复合物中存在的蛋白质的数量和类型相关的读数。

公开(公告)号：US20060199231A1

公开(公告)日：2006-09-07

申请号：US11267870

申请日：2005-11-03

申请人： Sean Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

发明人： Sean Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

IPC分类号： G01N33/574

CPC分类号： G01N33/5041 ,  G01N33/5064 ,  G01N33/5091 ,  G01N33/574 ,  G01N2333/515 ,  G01N2333/71 ,  G01N2800/52 ,  Y10S436/824

摘要： Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.

摘要翻译： 提供了方法，组合物和试剂盒，用于通过敏感，直接检测分子水平的内皮细胞活化来评估血管发生。 通常，通过测量参与内皮细胞中特异性血管生成信号传导途径的细胞成分及其蛋白质复合物的水平来检测内皮细胞的活化。 该方法可以用于评估与不期望的血管生成相关的疾病的状态，例如发展疾病的可能性，疾病的存在或不存在，疾病的预后以及对特定抗血管生成疗法的反应或抗性的可能性。 该方法还可用于指导针对特定血管生成信号通路的有效治疗方案的设计，以及与不期望的血管发生相关的疾病或病症的治疗干预。

公开(公告)号：US20050170439A1

公开(公告)日：2005-08-04

申请号：US11041073

申请日：2005-01-21

申请人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

发明人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

IPC分类号： A61K31/275 ,  G01N33/53 ,  G01N33/542 ,  G01N33/567 ,  G01N33/574 ,  G01N33/68

CPC分类号： G01N33/542 ,  G01N33/57492 ,  G01N33/6803 ,  G01N33/6842 ,  G01N33/6872 ,  G01N2333/485 ,  G01N2333/49 ,  G01N2800/52

摘要： Abstract of the Disclosure The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

摘要翻译： 摘要揭示本发明涉及一种包含ErbB细胞表面膜受体二聚体的患者样品中的一类新生物标志物。 在一个方面，本发明包括通过将这样的病症与在患者样品，特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面，本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症的状态的方法，包括存在或 不存在癌前状态，存在或不存在癌症状态，癌症预后或对治疗的反应性。 优选地，本发明的方法通过使用具有可释放分子标签的结合化合物来实现，所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后，分离标签被释放并与测定混合物分离，用于分析。

公开(公告)号：US06900021B1

公开(公告)日：2005-05-31

申请号：US09080546

申请日：1998-05-18

申请人： Daniel Jed Harrison ,  Per Andersson ,  Paul C. H. Li ,  Roderick Szarka ,  Richard Smith ,  Hossein Salimi-Moosavi

发明人： Daniel Jed Harrison ,  Per Andersson ,  Paul C. H. Li ,  Roderick Szarka ,  Richard Smith ,  Hossein Salimi-Moosavi

IPC分类号： G01N33/49 ,  B01J19/00 ,  B01J19/08 ,  B01L3/00 ,  B81B1/00 ,  G01N33/15 ,  G01N33/50 ,  G01N37/00 ,  G01N33/554

CPC分类号： B01L3/502761 ,  B01F13/0059 ,  B01J19/0093 ,  B01L2200/0668 ,  B01L2300/0816 ,  B01L2300/0864 ,  B01L2300/0867 ,  B01L2400/0415 ,  B01L2400/0487 ,  B81B1/00 ,  Y10T436/117497

摘要： This invention relates to a novel microfluidic device and methods of using this device to conduct in vitro studies on the reaction and effects of various compounds on cells. More particularly, it relates to a method for using stop flow in a microfluidic system to study the effect of compounds on individual cells. It also provides a method for observing the effects of candidate compounds on leukocyte rolling.

摘要翻译： 本发明涉及一种新颖的微流体装置和使用该装置进行体外研究各种化合物对细胞的反应和作用的方法。 更具体地说，本发明涉及一种在微流体系统中使用停止流动来研究化合物对单个细胞的影响的方法。 它还提供了观察候选化合物对白细胞滚动的影响的方法。

公开(公告)号：US06224830B1

公开(公告)日：2001-05-01

申请号：US09016142

申请日：1998-01-30

申请人： D. Jed Harrison ,  Graham H. McKinnon ,  Nghia H. Chiem ,  Gregor Ocvirk ,  Hossein Salimi-Moosavi ,  Yutao Jiang

发明人： D. Jed Harrison ,  Graham H. McKinnon ,  Nghia H. Chiem ,  Gregor Ocvirk ,  Hossein Salimi-Moosavi ,  Yutao Jiang

IPC分类号： G01N2101

CPC分类号： G01N21/03 ,  G01N27/44721 ,  G01N2021/0346

摘要： An improved absorbance or detection cell for a microfluid device, and in accordance with an aspect of the invention, the absorbance cell comprises a bottom plate having a channel bearing surface in which a channel having a fluid inlet and fluid outlet is defined, a top plate having a channel facing surface bound to the channel bearing surface of the bottom plate and first and second reflecting elements formed on opposed sides of the channel to form a waveguide through which the channel extends such that radiation propagating along the waveguide makes multiple passes across the channel, the waveguide having a radiation input end and a radiation output end.

摘要翻译： 用于微流体装置的改进的吸光度或检测单元，并且根据本发明的一个方面，吸光度单元包括底板，其具有通道支承表面，在该底板中限定了具有流体入口和流体出口的通道，顶板 具有与所述底板的通道支承表面结合的通道面向表面，以及形成在所述通道的相对侧上的第一和第二反射元件，以形成所述通道延伸的波导，使得沿着所述波导传播的辐射使所述通道 波导具有辐射输入端和辐射输出端。